{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:27:46Z","timestamp":1791221266822,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ejim.2023.01.005","type":"journal-article","created":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T06:56:13Z","timestamp":1673160973000},"page":"10-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Pathophysiology of cough with angiotensin-converting enzyme inhibitors: How to explain within-class differences?"],"prefix":"10.1016","volume":"110","author":[{"given":"Claudio","family":"Borghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrigo FG","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Agnoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Fiorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ejim.2023.01.005_bib001","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","article-title":"Angiotensin- converting enzyme inhibitors in hypertension: to use or not to use?","volume":"71","author":"Messerli","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ejim.2023.01.005_bib002","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ajh\/hpw121","article-title":"AT2 receptors: potential therapeutic targets for hypertension","volume":"30","author":"Carey","year":"2017","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejim.2023.01.005_bib003","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction: results of the survival and ventricular enlargement trial","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.01.005_bib004","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.01.005_bib005","first-page":"821","article-title":"The Acute Infarction Ramipril Efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.01.005_bib006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)09374-X","article-title":"Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction","volume":"354","author":"Torp-Pedersen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.01.005_bib007","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"The heart outcomes prevention evaluation study investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.01.005_bib008","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2023.01.005_bib009","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejim.2023.01.005_bib0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1586\/erc.09.2","article-title":"Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease","volume":"7","author":"Brugts","year":"2009","journal-title":"Expert Rev Cardiovasc"},{"issue":"6","key":"10.1016\/j.ejim.2023.01.005_bib0011","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 international society of hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.ejim.2023.01.005_bib0012","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"issue":"19","key":"10.1016\/j.ejim.2023.01.005_bib0013","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"ACC\/AHA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"71","author":"Whelton","year":"2017","journal-title":"JACC"},{"issue":"2","key":"10.1016\/j.ejim.2023.01.005_bib0014","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HJH.0000000000000447","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs \u2013 Overview and meta-analyses","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"J Hypertens"},{"issue":"5","key":"10.1016\/j.ejim.2023.01.005_bib0015","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"9489","key":"10.1016\/j.ejim.2023.01.005_bib0016","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet."},{"key":"10.1016\/j.ejim.2023.01.005_bib0017","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejim.2023.01.005_bib0018","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/HJH.0000000000002294","article-title":"Medication adherence in hypertension","volume":"38","author":"Poulter","year":"2020","journal-title":"J Hypertens"},{"issue":"6","key":"10.1016\/j.ejim.2023.01.005_bib0019","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1042\/CS20130204","article-title":"Genetic variation and gender determine bradykinin type 1 receptor responses in human tissue: implications for the ACE-inhibitor-induced effects in patients with coronary artery disease","volume":"126","author":"Wu","year":"2014","journal-title":"Clin Sci"},{"issue":"5","key":"10.1016\/j.ejim.2023.01.005_bib0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ihj.2020.08.007","article-title":"ShahN. ACEI-induced cough: a review of current evidence and its practical implications for optimal CV risk reduction","volume":"72","author":"Pinto","year":"2020","journal-title":"Indian Heart J"},{"issue":"3","key":"10.1016\/j.ejim.2023.01.005_bib0021","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cpt.1018","article-title":"The true rate of angiotensin converting enzyme inhibitors related cough in placebo-controlled trials: a meta-analysis","volume":"105","author":"Vukadinovi\u0107","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ejim.2023.01.005_bib0022","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/cpt.1040","article-title":"Cough and ACE Inhibitors: the Truth Beyond Placebo","volume":"105","author":"Borghi","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2023.01.005_bib0023","article-title":"Factors that favor the occurrence of cough in patients treated with ramipril e a pharmacoepidemiological study","volume":"18","author":"Wyskida","year":"2012","journal-title":"Med Sci Mon Int Med J Exp Clin Res"},{"issue":"1","key":"10.1016\/j.ejim.2023.01.005_bib0024","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/jpbs.JPBS_308_16","article-title":"Efficacy and tolerability of antihypertensive drugs in diabetic and nondiabetic patients","volume":"9","author":"Aslam","year":"2017","journal-title":"J Pharm Bioallied Sci"},{"key":"10.1016\/j.ejim.2023.01.005_bib0025","doi-asserted-by":"crossref","first-page":"135e142","DOI":"10.1007\/BF03256570","article-title":"Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG perspective, observational, multicenter study","volume":"9","author":"Bahl","year":"2009","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ejim.2023.01.005_bib0026","first-page":"141","article-title":"Incidence of recurrent stroke in primary care during preventive treatment based on perindopril with or without indapamide","volume":"55","author":"Mv","year":"2007","journal-title":"Neurol\u00a0India"},{"key":"10.1016\/j.ejim.2023.01.005_bib0027","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ijcard.2014.07.108","article-title":"The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease","volume":"176","author":"Brugts","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2023.01.005_bib0028","doi-asserted-by":"crossref","first-page":"36e42","DOI":"10.5152\/TurkThoracJ.2018.18014","article-title":"Angiotensin-converting enzyme inhibitors induce cough","volume":"20","author":"Y\u0131lmaz","year":"2019","journal-title":"Turk Thorac J"},{"key":"10.1016\/j.ejim.2023.01.005_bib0029","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1378\/chest.95.3.544","article-title":"Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors","volume":"95","author":"Kaufman","year":"1989","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2023.01.005_bib0030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/bmj.296.6615.86","article-title":"Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors","volume":"296","author":"Bucknall","year":"1988","journal-title":"Br Med J"},{"key":"10.1016\/j.ejim.2023.01.005_bib0031","doi-asserted-by":"crossref","first-page":"922e925","DOI":"10.1378\/chest.101.4.922","article-title":"Angiotensin-converting enzyme inhibitors in patients with bronchial responsiveness and asthma","volume":"101","author":"Kaufman","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2023.01.005_bib0032","doi-asserted-by":"crossref","first-page":"265e270","DOI":"10.1111\/j.1365-2125.1995.tb04447.x","article-title":"Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril. A controlled retrospective cohort study","volume":"39","author":"Wood","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2023.01.005_bib0033","first-page":"76","article-title":"Captopril and bronchial reactivity","volume":"62","author":"Sala","year":"1986","journal-title":"Postgrad Med"},{"issue":"3","key":"10.1016\/j.ejim.2023.01.005_bib0034","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2217\/pgs-2018-0157","article-title":"Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis","volume":"20","author":"Mu","year":"2019","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ejim.2023.01.005_bib0035","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/sj.jhh.1001486","article-title":"Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough","volume":"16","author":"Mukae","year":"2002","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.ejim.2023.01.005_bib0036","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jclinepi.2006.06.017","article-title":"Dechallenge and rechallenge method showed different incidences of cough among four ACE-Is","volume":"60","author":"Tumanan-Mendoza","year":"2007","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ejim.2023.01.005_bib0037","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1586\/14779072.3.1.15","article-title":"Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril","volume":"3","author":"Ferrari","year":"2005","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.ejim.2023.01.005_bib0038","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0002-9149(92)90630-H","article-title":"Spontaneous disappearance of cough induced by angiotensin-converting enzyme inhibitors (captopril or enalapril)","volume":"70","author":"Reisin","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2023.01.005_bib0039","first-page":"333","article-title":"Complete spontaneous remission of cough induced by ACE inhibitors during chronic therapy in hypertensive patients","volume":"6","author":"Reisin","year":"1992","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.ejim.2023.01.005_bib0040","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/10641963.2015.1026040","article-title":"A prospective study of frequency and characteristics of cough during ACE inhibitor treatment","volume":"37","author":"Sato","year":"2015","journal-title":"Clin Exp Hypertens"},{"issue":"2","key":"10.1016\/j.ejim.2023.01.005_bib0041","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2125.1995.tb04418.x","article-title":"Reproducibility of angiotensin converting enzyme inhibitor induced cough: a double-blind randomised study","volume":"39","author":"Charlon Dollow","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ejim.2023.01.005_bib0042","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2125.1999.00855.x","article-title":"Cough and angiotensin II receptor antagonists: cause or confounding?","volume":"47","author":"Mackay","year":"1999","journal-title":"Br J Clin Pharmacol"},{"issue":"16","key":"10.1016\/j.ejim.2023.01.005_bib0043","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMcp1414215","article-title":"Chronic cough","volume":"375","author":"Smith","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2023.01.005_bib0044","first-page":"515e520","article-title":"Enalapril and diltiazem coadministration and respiratory side effects of enalapril","volume":"54","author":"Franova","year":"2005","journal-title":"Physiol Res"},{"key":"10.1016\/j.ejim.2023.01.005_bib0045","first-page":"309e313","article-title":"The influence of inhaled furosemide on adverse effects of ACEi-nhibitors in airways","volume":"102","author":"Franova","year":"2001","journal-title":"Bratisl Lek List"},{"key":"10.1016\/j.ejim.2023.01.005_bib0046","doi-asserted-by":"crossref","first-page":"169S","DOI":"10.1378\/chest.129.1_suppl.169S","article-title":"Angiotensin-converting enzyme inhibitor induced cough","volume":"129","author":"Dicpinigaitis","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2023.01.005_bib0047","first-page":"157","article-title":"Cough and angioedema in patients receiving angiotensin-converting enzyme inhibitors. Are they always attributable to medication?","volume":"79","author":"Sebastian","year":"2011","journal-title":"Rev Argent Cardiol"},{"key":"10.1016\/j.ejim.2023.01.005_bib0048","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0253-7613.62408","article-title":"Adverse drug reaction monitoring with angiotensin converting enzyme inhibitors: a prospective, randomized, open-label, comparative study","volume":"42","author":"Sangole","year":"2010","journal-title":"Indian J Pharmacol"},{"issue":"4","key":"10.1016\/j.ejim.2023.01.005_bib0049","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/1074248410379413","article-title":"Effects of Zofenopril and Ramipril on cough reflex responses in anesthetized and awake rabbits","volume":"15","author":"Mutolo","year":"2010","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ejim.2023.01.005_bib0050","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00210-010-0563-0","article-title":"Differences between zofenopril and ramipril, two ACE inhibitors, on cough induced by citric acid in guinea pigs: role of bradykinin and PGE2","volume":"382","author":"Cialdai","year":"2010","journal-title":"Naunyn Schmiedeberg Arch Pharmacol"},{"issue":"5","key":"10.1016\/j.ejim.2023.01.005_bib0051","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/HJH.0b013e32834550d0","article-title":"Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class","volume":"29","author":"Mancia","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2023.01.005_bib0052","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ijcard.2014.07.108","article-title":"The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease","volume":"176","author":"Brugts","year":"2014","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2023.01.005_bib0053","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/FJC.0b013e3181e5f2e2","article-title":"Atorvastatin protects against angiotensin II-induced injury and dysfunction in human umbilical vein endothelial cells through bradykinin 2 receptors","volume":"56","author":"Zhang","year":"2010","journal-title":"Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2023.01.005_bib0054","doi-asserted-by":"crossref","first-page":"21","DOI":"10.18087\/cardio.2018.9.10170","article-title":"Combined therapy of arterial hypertension with triple fixed-dose combination of amlodipine\/indapamide\/perindopril arginine in real clinical practice: the organization and the main results of the DOKAZATEL'STVO (Proof) study","volume":"58","author":"Kobalava","year":"2018","journal-title":"Kardiologiia"},{"key":"10.1016\/j.ejim.2023.01.005_bib0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40256-014-0067-2","article-title":"PIANIST Investigators: antihypertensive efficacy of triple combination perindopril\/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hypertensive patients)","volume":"14","author":"Toth","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ejim.2023.01.005_bib0056","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s40261-014-0223-0","article-title":"Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR","volume":"34","author":"Pall","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ejim.2023.01.005_bib0057","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s12325-017-0572-1","article-title":"The antihypertensive efficacy of the triple fixed combination of perindopril, indapamide, and amlodipine: the results of the PETRA study","volume":"34","author":"Abrah\u2002am","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.ejim.2023.01.005_bib0058","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF03256570","article-title":"Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG perspective, observational, multicenter study","volume":"9","author":"Bahl","year":"2009","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ejim.2023.01.005_bib0059","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4103\/0028-3886.32785","article-title":"Incidence of recurrent stroke in primary care during preventive treatment based on perindopril with or without indapamide","volume":"55","author":"Padma","year":"2007","journal-title":"Neurol India"},{"key":"10.1016\/j.ejim.2023.01.005_bib0060","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ihj.2014.10.419","article-title":"Blood pressure control and acceptability of Perindopril and its fixed dose combinations with Amlodipine or Indapamide, in younger patients with hypertension","volume":"66","author":"Bansal","year":"2014","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ejim.2023.01.005_bib0061","first-page":"459","article-title":"Zofenopril and incidence of cough: a review of published and unpublished data","volume":"7","author":"Borghi","year":"2011","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"10.1016\/j.ejim.2023.01.005_bib0062","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40292-015-0120-5","article-title":"Role of the Renin-Angiotensin-Aldosterone System and its pharmacological inhibitors in cardiovascular disease: complex and critical issues","volume":"22","author":"Borghi","year":"2015","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.ejim.2023.01.005_bib0063","doi-asserted-by":"crossref","unstructured":"Tsioufis K, Douma S, Kallistratos MS, Manolis AJ. Effectiveness and adherence to treatment with perindopril\/indapamide\/amlodipine single-pill combination in a Greek population with hypertension. Clin Drug Invest. 2019;39:385\u2013393.","DOI":"10.1007\/s40261-019-00761-0"},{"key":"10.1016\/j.ejim.2023.01.005_bib0064","doi-asserted-by":"crossref","unstructured":"Nedogoda SV, Stojanov VJ. Single-pill combination of perindopril\/indapamide\/ amlodipine in patients with uncontrolled hypertension: a randomized controlled trial. Cardiol therapy. 2017; 6:91\u2013104.","DOI":"10.1007\/s40119-017-0085-7"},{"key":"10.1016\/j.ejim.2023.01.005_bib0065","doi-asserted-by":"crossref","unstructured":"Mourad J-J, Amodeo C, de Champvallins M, Brzozowska-Villatte R, Asmar R.Blood pressure-lowering efficacy and safety of perindopril\/indapamide\/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial. J Hypertens. 2017; 35:1481\u20131495.","DOI":"10.1097\/HJH.0000000000001359"},{"key":"10.1016\/j.ejim.2023.01.005_bib0066","doi-asserted-by":"crossref","unstructured":"Sampalis JS, Psaradellis E, Stutz M, Rickard J, Rampakakis E. Post Hoc Analysis of the CONFIDENCE II, PROTECT I, SHAKE THE HABIT I and SHAKE THE HABIT II observational studies in mild to moderate hypertensive patients treated with perindopril and atorvastatin concomitantly. Drugs R. 2018; 18:283\u2013293.","DOI":"10.1007\/s40268-018-0255-7"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523000109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523000109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:38:05Z","timestamp":1760607485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523000109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":66,"alternative-id":["S0953620523000109"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.01.005","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiology of cough with angiotensin-converting enzyme inhibitors: How to explain within-class differences?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}